Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $264.8 million.

  • Akebia Therapeutics' Shares Outstanding (Weighted Average) rose 2587.99% to $264.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $264.8 million, marking a year-over-year increase of 2587.99%. This contributed to the annual value of $210.9 million for FY2024, which is 1252.56% up from last year.
  • As of Q3 2025, Akebia Therapeutics' Shares Outstanding (Weighted Average) stood at $264.8 million, which was up 2587.99% from $262.6 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $264.8 million for Q3 2025, and its period low was $153.8 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $186.8 million (2023), whereas its average is $196.4 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 175.37% in 2023, then soared by 2587.99% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $165.9 million in 2021, then increased by 10.14% to $182.8 million in 2022, then rose by 2.56% to $187.5 million in 2023, then rose by 12.53% to $210.9 million in 2024, then rose by 25.52% to $264.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $264.8 million for Q3 2025, versus $262.6 million for Q2 2025 and $235.5 million for Q1 2025.